Grassmuno® marketing authorisation in Germany

AI SummaryClose X

Allergy Therapeutics plc has received marketing authorisation from the German regulatory authority, the Paul Ehrlich Institut, for its subcutaneous grass pollen allergen immunotherapy, Grassmuno®, marking the first such approval under Germany's TAV program. This approval, based on a comprehensive package of quality, safety, and clinical efficacy data, including a significant reduction in the Combined Symptom & Medication Score in a Phase III trial, is expected to drive commercialisation in Germany in the first quarter of 2026. The German seasonal allergy market is projected to reach approximately US$1 billion by 2030, and the company is pursuing expansion strategies for Grassmuno® in other major global markets.

Disclaimer*

UK 100

Latest directors dealings